Why Zynerba's stock soared 62% this week

Zynerba's stock price closed up 62 percent Thursday, at $9.44 per share, after the specialty pharmaceutical company posted positive study results from a midstage clinical trial of its experimental treatment for a rare developmental disorder. The Devon company is attempting to develop synthetic cannabinoid-based therapies for a variety of disorders. Zynerba said in a study of its ZYN002 cannabidiol gel in pediatric and adolescent patients with Fragile X syndrome that the new drug candidates met…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news